CSL Behring announced that Tyler Reitano from the Cascade Foundation of Southern Arizona and Maklain Briggs from the Utah Hemophilia Foundation are the national winners of the 2015 Gettin’ in the GameSM Junior National Championship (JNC) program in golf and baseball, respectively. The JNC, launched in 2002, is CSL Behring’s annual baseball and golf competition that encourages kids to remain active despite the challenges a bleeding disorder can pose, while allowing them to develop life-long connections with other members of the community.
“Through innovative products and programs, CSL Behring helps people with life threatening medical conditions live full lives,” said Bill Campbell, Senior Vice President and General Manager, North America, CSL Behring. “The JNC is one program that delivers on our promise of making a real and lasting difference in the lives of people in the bleeding disorders community. Congratulations to Tyler and Maklain and all of the competitors who participated in this year’s event.”
CSL Behring’s JNC program is the first and only national golf and baseball competition designed specifically for the bleeding disorders community. In addition to the competitive activities, this event provides children and their caregivers with educational information and opportunities to interact with others in the community. The JNC features accomplished athletes, who themselves have been diagnosed with a bleeding disorder. These athletes hold clinics to help educate children and their families about the fundamentals of golf and baseball and share their stories with participants to encourage them to remain active as a part of managing their condition.
For more information about the JNC program or the wide variety of resources for the bleeding disorders community offered by CSL Behring, please visit www.MySourceCSL.com. CSL Behring’s My Source program provides one-stop access to educational information, financial support and community connections to individuals living with hemophilia and/or VWD.
About CSL Behring
The people and science of CSL Behring save lives around the world. We develop and deliver innovative specialty biotherapies, driven by our 100-year promise to help people with life-threatening conditions live full lives. With 14,000 employees and operations in 30 countries, CSL applies world-class R&D, high-quality manufacturing and patient-centered management.
CSL Behring therapies are used around the world to treat coagulation disorders including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders in certain markets. The company’s products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn.
CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma. CSL Behring is a global biopharmaceutical company and a member of the CSL Group of companies. The parent company, CSL Limited (ASX:CSL), is headquartered in Melbourne, Australia. For more information, visit www.cslbehring.com.